| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.007 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.089 | 0.007 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.007 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.091 | 0.007 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.093 | 0.008 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | -0.088 | 0.008 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.08 | 0.008 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | -0.084 | 0.009 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | -0.095 | 0.009 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.14 | 0.009 |